Primary Investigator First Name: *
Primary Investigator Last Name: *
Email: *
Secondary Email:
Office Phone Number: *
Mobile Phone Number:
Other Phone Number:
Address: *
Address #2:
Address #3:
City: *
State:
Other Alabama Alaska American Samoa Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Federated States of Micronesia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Marshall Islands Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Northern Mariana Islands Ohio Oklahoma Oregon Palau Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming ----Armed Forces---- AA: Americas AE: Europe/Middle East AP: Pacific
Country: *
Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Ascension Island Australia Austria Azerbaijan Bahamas Bahrain Barbados Bangladesh Belarus Belgium Belize Benin Bermuda Bhutan Botswana Bolivia Bosnia and Herzegovina Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, Democratic Republic Cook Islands Costa Rica Cote D'Ivoire (Ivory Coast) Croatia (Hrvatska) Cuba Cyprus Czech Republic Czechoslovakia (former) Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France France, Metropolitan French Guiana French Polynesia French Southern Territories F.Y.R.O.M. (Macedonia) Gabon Gambia Georgia Germany Ghana Gibraltar Great Britain (UK) Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Isle of Man Italy Jersey Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea (North) Korea (South) Kuwait Kyrgyzstan Laos Latvia Lebanon Liechtenstein Liberia Libya Lesotho Lithuania Luxembourg Macau Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles Neutral Zone New Caledonia New Zealand (Aotearoa) Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda S. Georgia and S. Sandwich Isls. Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovenia Slovak Republic Solomon Islands Somalia South Africa Spain Sri Lanka St. Helena St. Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America US Minor Outlying Islands Uruguay USSR (former) Uzbekistan Vanuatu Vatican City State (Holy See) Venezuela Viet Nam British Virgin Islands Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia (former) Zambia Zimbabwe Other
Zip Code: *
Affiliated Institution(s) and/or Companies: *
Primary Research Institution: *
Involved Departments and/or Research Institutions: *
Title(s) (with respect to each department): *
Date of Hire:
Title of Proposed Human Cancer Treatment Clinical Trial:
If Yes, what was the date and title of the proposed Study?:
Primary Area of Research: *
Anal Cancer Bladder Cancer Bone Cancer Brain Cancer Breast Cancer Cervical Cancer Colon and Rectal Cancer Endometrial Cancer Eye Cancer Gastric Cancer Head and Neck Hodgkin's Lymphoma Kidney (Renal Cell) Cancer Leukemia Liver Cancer Lung Cancer Melanoma Multiple Myeloma Multiple Site Non-Hodgkin Lymphoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Sarcoma/Bone Cancer Skin Cancer (Non-melanoma) Stomach Cancer Testicular Cancer Thyroid Cancer Uterine Cancer Vaginal Cancer Other
How many patients will you treat in this trial (and what are the cohorts)? : *
What is the total cost, standards of care cost, and additional study cost?: *
If the approvals have not yet been recieved, what is your timeline for receiving the approvals? : *
How many patients will you enroll in this trial each month upon receipt of The Gateway funding? : *
What do you expect your treatment to do for these patients? (Therapeutic vs. Research intent): *
Why do you expect your treatment to work for the patients in the study?: *
What will be done for patients with positive results who are near completion or have finished their treatment plans but are not cured?: *
If not, why?:
How many years do you expect this trial to take in its entirety?: *
One Two Three Four Five
Why?: *
After receiving The Gateway funding when will you provide us reports on results you are seeing with this trial?: *
1 month 2 months 3 months 4-6 months 6-12 months 12-24 months
How many patients have you treated in all your past clinical trials combined -PERSONALLY?: *
0-5 6-10 11-20 21-49 50+
How many patients have you treated in all your past clinical trials combined -AS A DEPARTMENT?: *
0-5 6-10 11-20 21-49 50+
How many patients are you currently treating in general now- PERSONALLY?: *
0-5 6-10 11-20 21-49 50+
How many patients are you currently treating in general now- AS A DEPARTMENT?: *
0-5 6-10 11-20 21-49 50+
What does your typical weekly work schedule look like day-by-day?: *
How many of your current patients are participating in a clinical trial in which you are currently collaborating and/or another in which you encouraged them to participate? ( please denote each separately) : *
How EXACTLY is the Gateway money you receive going to be spent? (Attach your VERY DETAILED budget and expenses sheet): *
What are the next steps if your treatment results successfully meet this trial’s objectives?: *
At which point(s) will you voluntarily shut down this trial and/or propose changes for higher patient impact?: *
What is your personal motivation for conducting this trial?: *
Why did you choose the institution(s)/company where you work?: *
What is your brief analysis of the 20-year scope of research and progress regarding and related to this proposed clinical treatment trial?: *
How many professionals outside of your current institution(s)/company have you consulted regarding viability and /or orginally of this proposed clincial treatment trial: *
0 1-3 2-5 5-10 10+
Please describe any machinery to be used in this trial (brand, model, year of make, etc.).: *
I would like to receive email updates from The Gateway for Cancer Research.
I would like to allow The Gateway for Cancer Research to show my response on this website.